Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Advanced Technologies for Antigen Identification
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Advanced Technologies for Antigen Identification
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Editorial

  • Editorial
    A New Cancer Immunology Research Special Feature: Perspective from a Master of Immunology
    Glenn Dranoff
    Cancer Immunol Res October 1 2014 2 (10) 925-925; DOI:10.1158/2326-6066.CIR-14-0166

Perspective from a Master of Immunology

  • Perspective from a Master of Immunology
    The Path to Reactivation of Antitumor Immunity and Checkpoint Immunotherapy
    Hye-Jung Kim and Harvey Cantor
    Cancer Immunol Res October 1 2014 2 (10) 926-936; DOI:10.1158/2326-6066.CIR-14-0153

Cancer Immunology at the Crossroads: Microbiology

  • Cancer Immunology at the Crossroads: Microbiology
    HPV Infection–Associated Cancers: Next-Generation Technology for Diagnosis and Treatment
    Cornelia L. Trimble
    Cancer Immunol Res October 1 2014 2 (10) 937-942; DOI:10.1158/2326-6066.CIR-14-0152

Priority Brief

  • Priority Brief
    Assessment of MAGE-A Expression in Resected Non–Small Cell Lung Cancer in Relation to Clinicopathologic Features and Mutational Status of EGFR and KRAS
    Maha Ayyoub, Lorenzo Memeo, Emilio Álvarez-Fernández, Cristina Colarossi, Rosario Costanzo, Eleonora Aiello, Daniela Martinetti and Danila Valmori
    Cancer Immunol Res October 1 2014 2 (10) 943-948; DOI:10.1158/2326-6066.CIR-13-0211

    Ayyoub and colleagues show that MAGE-A expression occurs primarily in squamous tumors and is correlated with high tumor grade and poorer survival, whereas EGFR and KRAS mutations occur in adenocarcinomas but not in squamous tumors, with KRAS mutations associated with early-stage disease and better survival.

Research Articles

  • Research Articles
    A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF–Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer
    Gang Chen, Richa Gupta, Silvia Petrik, Marina Laiko, James M. Leatherman, Justin M. Asquith, Maithili M. Daphtary, Elizabeth Garrett-Mayer, Nancy E. Davidson, Kellie Hirt, Maureen Berg, Jennifer N. Uram, Tianna Dauses, John Fetting, Elizabeth M. Duus, Saadet Atay-Rosenthal, Xiaobu Ye, Antonio C. Wolff, Vered Stearns, Elizabeth M. Jaffee and Leisha A. Emens
    Cancer Immunol Res October 1 2014 2 (10) 949-961; DOI:10.1158/2326-6066.CIR-14-0058

    Chen and colleagues show in patients and in a mouse model of HER2+ breast cancer that abrogating immune suppression with low-dose cyclophosphamide along with administration of an allogeneic GM-CSF–secreting HER2+ tumor vaccine and trastuzumab weekly augmented HER2-specific T-cell responses and survival.

  • Research Articles
    Association Studies of Fcγ Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831
    Nadine Norton, Rebecca M. Olson, Mark Pegram, Kathleen Tenner, Karla V. Ballman, Raphael Clynes, Keith L. Knutson and Edith A. Perez
    Cancer Immunol Res October 1 2014 2 (10) 962-969; DOI:10.1158/2326-6066.CIR-14-0059

    Norton, Olson, and colleagues found no differences in disease-free survival in trastuzumab-treated patients regardless of their FCGR2A and FCGR3A genotypes, but a significant difference between patients with FCGR2B variants, suggesting the functionality of FCGR2B may predict benefit to trastuzumab.

  • Research Articles | AuthorChoice
    Cytotoxic T Lymphocyte Antigen-4 Blockade Enhances Antitumor Immunity by Stimulating Melanoma-Specific T-cell Motility
    Tsvetelina Pentcheva-Hoang, Tyler R. Simpson, Welby Montalvo-Ortiz and James P. Allison
    Cancer Immunol Res October 1 2014 2 (10) 970-980; DOI:10.1158/2326-6066.CIR-14-0104

    Pentcheva-Hoang and colleagues analyzed melanoma-specific T-cell dynamics in tumors and tumor-draining lymph nodes before and after immune checkpoint blockade, and their study demonstrates that successful immunotherapy correlates with greater T-cell motility and reversal of the T-cell paralysis in growing tumors.

  • Research Articles
    Adjuvant Vaccine Immunotherapy of Resected, Clinically Node-Negative Melanoma: Long-term Outcome and Impact of HLA Class I Antigen Expression on Overall Survival
    William E. Carson III, Joseph M. Unger, Jeffrey A. Sosman, Lawrence E. Flaherty, Ralph J. Tuthill, Mark J. Porter, John A. Thompson, Raymond A. Kempf, Megan Othus, Antoni Ribas and Vernon K. Sondak
    Cancer Immunol Res October 1 2014 2 (10) 981-987; DOI:10.1158/2326-6066.CIR-14-0052

    A final report of trial S9035 by Carson and colleagues indicates a significant overall benefit from the lysed adjuvant vaccine melacrine for patients with stage II to IV melanoma with HLA A2 and/or HLA Cw3 serotypes, implicating interactions between HLA haplotype and clinical outcome.

  • Research Articles
    A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T
    Douglas G. McNeel, Thomas A. Gardner, Celestia S. Higano, Philip W. Kantoff, Eric J. Small, Mark H. Wener, Robert B. Sims, Todd DeVries, Nadeem A. Sheikh and Robert Dreicer
    Cancer Immunol Res October 1 2014 2 (10) 988-999; DOI:10.1158/2326-6066.CIR-14-0073

    McNeel and colleagues demonstrate that a transient increase in eosinophil counts following sipuleucel-T treatment was associated with therapy-induced immune responses and longer prostate cancer survival, suggesting this could be prospectively evaluated as a biomarker in clinical trials.

  • Research Articles
    Phenotypic and Functional Activation of Hyporesponsive KIRnegNKG2Aneg Human NK-Cell Precursors Requires IL12p70 Provided by Poly(I:C)-Matured Monocyte-Derived Dendritic Cells
    Shane A. Curran, Emanuela Romano, Michael G. Kennedy, Katharine C. Hsu and James W. Young
    Cancer Immunol Res October 1 2014 2 (10) 1000-1010; DOI:10.1158/2326-6066.CIR-14-0054-T

    Curran and colleagues show that IL12p70 from human DCs induces NK-cell precursors to transition from KIR/NKG2A-negative to positive and become functionally active, providing a rationale for generating donor NK cells against missing KIR ligands to enhance the graft-versus-leukemia effect after allogeneic HSCT.

  • Research Articles
    TGFβ Inhibition Prior to Hypofractionated Radiation Enhances Efficacy in Preclinical Models
    Kristina H. Young, Pippa Newell, Benjamin Cottam, David Friedman, Talicia Savage, Jason R. Baird, Emmanuel Akporiaye, Michael J. Gough and Marka Crittenden
    Cancer Immunol Res October 1 2014 2 (10) 1011-1022; DOI:10.1158/2326-6066.CIR-13-0207

    Young and colleagues demonstrate in syngeneic mouse models of colorectal and pancreatic cancers that TGFβ inhibition with the oral, small-molecule inhibitor SM16 enhanced adaptive immunity in the tumor microenvironments and significantly improved the efficacy of subsequent radiotherapy.

Back to top
PreviousNext
Cancer Immunology Research: 2 (10)
October 2014
Volume 2, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

Jump to

  • Editorial
  • Perspective from a Master of Immunology
  • Cancer Immunology at the Crossroads: Microbiology
  • Priority Brief
  • Research Articles
Advertisement
  • Most Cited
  • Most Read
Loading
  • Activity of Anti-CTLA-4 Isotypes in Antitumor Responses
  • Masters of Immunology
  • Extending Reach of Checkpoint Blockade in Pancreatic Cancer
  • Characterization of Murine Syngeneic Tumor Models
  • Case Report: RNA CAR T Cells
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement